Drug intelligence / Profile preview

NKTR-125

Development stage: Discontinued
Lead developer: Nektar Therapeutics
Modality: Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

NKTR-125 is an early-stage PEGylated version of recombinant human interleukin-2 (IL-2), developed by Nektar Therapeutics for the treatment of various cancers. It was designed using Nektar's proprietary polymer conjugation technology to extend the half-life of IL-2 and potentially improve its safety profile compared to high-dose aldesleukin (Proleukin). The mechanism involves binding to the IL-2 receptor complex to stimulate the proliferation and activation of effector T cells and natural killer (NK) cells. However, NKTR-125 was largely superseded in Nektar's development pipeline by NKTR-214 (bempegaldesleukin), a more optimized PEG-IL-2 prodrug designed for biased signaling toward the IL-2 receptor beta-gamma (IL-2Rβγ) complex.

Other names: PEGylated Interleukin-2PEG-IL-2PEG-IL2PEG-IL 2

Targets

IL2RB (IL-2 receptor beta chain)

Beyond the preview

Go deeper on NKTR-125.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NKTR-125.

Explore the full profile